1. IAEA Activities on 67 Cu, 186 Re, 47 Sc Theranostic Radionuclides and Radiopharmaceuticals.
- Author
-
Jalilian AR, Gizawy MA, Alliot C, Takacs S, Chakarborty S, Rovais MRA, Pupillo G, Nagatsu K, Park JH, Khandaker MU, Mikolajczak R, Bilewicz A, Okarvi S, Gagnon K, Al Rayyes AH, Lapi SE, Starovoitova V, Korde A, and Osso JA
- Subjects
- Cyclotrons, Humans, International Agencies, Quality Control, Copper Radioisotopes chemistry, Precision Medicine, Radioisotopes chemistry, Radioisotopes standards, Radiopharmaceuticals chemical synthesis, Radiopharmaceuticals standards, Rhenium chemistry, Scandium chemistry
- Abstract
Despite interesting properties, the use of
67 Cu,186 Re and47 Sc theranostic radionuclides in preclinical studies and clinical trials is curtailed by their limited availability due to a lack of widely established production methods. An IAEA Coordinated Research Project (CRP) was initiated to identify important technical issues related to the production and quality control of these emerging radionuclides and related radiopharmaceuticals, based on the request from IAEA Member States. The international team worked on targetry, separation, quality control and radiopharmaceutical aspects of the radionuclides obtained from research reactors and cyclotrons leading to preparation of a standard recommendations for all Member States. The CRP was initiated in 2016 with fourteen participants from thirteen Member States from four continents. Extraordinary results on the production, quality control and preclinical evaluation of selected radionuclides were reported in this project that was finalized in 2020. The outcomes, outputs and results of this project achieved by participating Member States are described in this minireview., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)- Published
- 2021
- Full Text
- View/download PDF